enGene Therapeutics (ENGN) Other Non-Current Liabilities (2022)
enGene Therapeutics (ENGN) posted quarterly Other Non-Current Liabilities of $11.5 million for Q4 2022.
enGene Therapeutics (ENGN) Other Non-Current Liabilities (2022) Analysis & Trends
enGene Therapeutics (ENGN) has reported Other Non-Current Liabilities for 1 consecutive years, with $11.5 million the latest figure, recorded in Q4 2022.
- In Q4 2022, Other Non-Current Liabilities changed N/A year-over-year to $11.5 million; the TTM figure through Oct 2022 stood at $11.5 million (changed N/A YoY), while the FY2022 annual figure was $11.5 million, changed N/A from the prior year.
- Other Non-Current Liabilities held at $11.5 million in Q4 2022 per ENGN's latest filing.
- Across five years, Other Non-Current Liabilities topped out at $11.5 million in Q4 2022 and bottomed at $11.5 million in Q4 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.60 Bn | 130.75 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.93 Bn | 77.93 Bn | 3.93 Bn |
| 3 | Argenx Se | 65.06 Bn | 59.88 Bn | 1.37 Bn |
| 4 | Moderna | 56.22 Bn | 51.08 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 42.03 Bn | 36.93 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.65 Bn | 28.34 Bn | 992.69 Mn |
| 7 | BioNTech SE | 27.70 Bn | 9.31 Bn | 668.28 Mn |
| 8 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.31 Bn | 26.48 Bn | - |
| 10 | enGene Therapeutics | 123.41 Mn | 123.41 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Oct 31, 2022 | 11.46 Mn |